VALEANT PHARMACEUTICALS INTL
VRX
VRX was delisted on the 27th of September, 2010.
2 hedge funds and large institutions have $414K invested in VALEANT PHARMACEUTICALS INTL in 2017 Q3 according to their latest regulatory filings, with funds opening new positions, 0 increasing their positions, 1 reducing their positions, and closing their positions.
0% more funds holding
Funds holding: 2 → 2 (0)
24% less capital invested
Capital invested by funds: $546K → $414K (-$132K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBI
Baxter Bros Inc
Riverside,
Connecticut
|
-$38.7K |
VRX Hedge Fund Activity: Q3 2017 in Review
2 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in VALEANT PHARMACEUTICALS INTL (VRX) for Q3 2017, worth a combined $414K — down 24% from $546K a quarter earlier.
Fund positioning in VRX was balanced in Q3 2017: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 1 trimmed.
The largest seller was Baxter Bros Inc, cutting an estimated $38.7K.
- 2 institutional investors held VALEANT PHARMACEUTICALS INTL (VRX) as of Q3 2017, unchanged from Q2 2017.
- Funds reported $414K of VALEANT PHARMACEUTICALS INTL stock for Q3 2017, down 24% quarter-over-quarter.
- 0 funds opened new VALEANT PHARMACEUTICALS INTL positions in Q3 2017 and 0 closed out.
- The largest VALEANT PHARMACEUTICALS INTL seller in Q3 2017 was Baxter Bros Inc, an estimated $38.7K sold.
Based on aggregated 13F filings for Q3 2017.